The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

By I. Hellström, J. Raycraft, M. Hayden-Ledbetter, J. Ledbetter, Michèl Schummer, M. McIntosh, C. Drescher, N. Urban, K. Hellström. Cancer Research, 2003

771 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/95a7bca1eb5529d87fbe925756e1185885c38ff6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Miller
2. Richard G. Moore
3. R. Bast
4. D. Mcmeekin
5. Amy K. Brown
6. P. DiSilvestro
7. M. Miller
8. Eleftherios P. Diamandis

Citations in the corpus

• The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. (2008, methodology): “We selected a panel of serum and urine biomarkers shown to be elevated in patients with ovarian cancer and which may complement the sensitivity and specificity of CA125 [12–18].”
• Methods of Microarray Data Analysis III (2003, methodology): “K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer.”
• Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool (2004, background): “Despite this reasonable hypothesis, very few cancer biomarkers have been discovered by using this approach (26, 27).”
• A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. (2009, background): “As well, HE4 is not elevated in many common benign gynecologic and medical conditions where CA125 is elevated [22].”